1. Scrip
  2. >>Business

Safety Issues Not Dampening AbbVie Optimism For Humira Successors

 
• By Joseph Haas

AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.

tests

AbbVie Inc. remains optimistic, despite some outside safety concerns, that its late-stage immunology drug candidates can increase its market share in autoimmune disease at a time when its top-selling powerhouse Humira (adalimumab) is facing increased competition from both biosimilars and new branded agents.

AbbVie talked up a number of pipeline milestones expected in the second half of 2017 during its July 28 second...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Just As The XBI Began Turnaround, Trump Upped MFN Pricing Threats

 
• By Mandy Jackson

Public Company Edition: The XBI fund attempted a correction midway through the week ending Aug. 1, but President Trump’s most favored nation drug pricing threats tanked valuations again. In financings, Leads Biolabs raised $189m in a Hong Kong IPO and Abivax closed a $747.5m FOPO.

Regulatory Setbacks Dim Otherwise Strong Quarter For Regeneron

 
• By Alaric DeArment

Eylea HD saw significant sales growth, but the company reported delays in FDA approvals for the drug and a CRL for its CD20xCD3-targeting bispecific for lymphomas.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By Manas Mishra

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

More from Scrip

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.